PEGylated Recombinant Human Growth Hormone Jintrolong<sup>®</sup> Exhibits Good Long-Term Safety in Cynomolgus Monkeys and Human Pediatric Growth Hormone Deficiency Patients.

Front Endocrinol (Lausanne) · 2022 · PMC9336684 · PMID 35909512

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Additionally, TEM examination of the brain CP also showed a trend toward recovery from vacuolation after a 104- and 157-week recovery period.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

PEGylated Recombinant Human Growth Hormone Jintrolong&lt;sup&gt;®&lt;/sup&gt; Exhibits Good Long-Term Safety in Cynomolgus Monkeys and Human Pediatric Growth Hormone Deficiency Patients.

The sentences

PEGylated Recombinant Human Growth Hormone Jintrolong<sup>®</sup> Exhibits Good Long-Term Safety in Cynomolgus Monkeys and Human Pediatric Growth Hormone Deficiency Patients.